Keeva McClelland

发表

FKBPL and Peptide Derivatives: Novel Biological Agents That Inhibit Angiogenesis by a CD44-Dependent Mechanism

D. Hirst, H. McCarthy, D. Waugh, 2011, Clinical Cancer Research.

Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.

Colin R. O'Dowd, T. Harrison, Elias Arkoudis, 2018, Nature chemical biology.

A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.

D. Hirst, H. McCarthy, C. Scott, 2008, Endocrinology.

BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells.

K. Rothkamm, K. Prise, S. A. Al Rashid, 2015, Cancer letters.

Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily.

J. Boros, D. M. Andrews, R. Ward, 2017, ACS chemical biology.

Cancer Therapy : Preclinical FKBPL and Peptide Derivatives : Novel Biological Agents That Inhibit Angiogenesis by a CD 44-Dependent Mechanism

D. Hirst, H. McCarthy, D. Waugh, 2011 .

That Inhibit Angiogenesis by a CD 44-Dependent Mechanism FKBPL and Peptide Derivatives : Novel Biological Agents

D. Hirst, H. McCarthy, D. Waugh, 2011 .

BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells.

K. Rothkamm, K. Prise, S. A. Al Rashid, 2015, Cancer letters.

Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen

J. F. Burrows, H. McCarthy, L. McClements, 2014, Oncogene.